- Home
- REPL vs RM Comparison
REPL vs RM Comparison
Compare REPL & RM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REPL | RM |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.1M | 334.1M |
| IPO Year | 2018 | 2011 |
Fundamental Metrics
Financial Performance| Metric | REPL | RM |
|---|---|---|
| Price | $11.52 | $38.98 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 1 |
| Target Price | $5.67 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 5.4M | 41.0K |
| Earning Date | 05-21-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.12% |
| EPS Growth | 5.25 | ★ 7.49 |
| EPS | N/A | ★ 1.18 |
| Revenue | N/A | ★ $645,598,000.00 |
| Revenue This Year | N/A | $12.94 |
| Revenue Next Year | N/A | $8.97 |
| P/E Ratio | ★ N/A | $32.97 |
| Revenue Growth | N/A | ★ 9.70 |
| 52 Week Low | $1.50 | $29.08 |
| 52 Week High | $13.24 | $46.00 |
Technical Indicators
Market Signals| Indicator | REPL | RM |
|---|---|---|
| Relative Strength Index (RSI) | 76.15 | 67.91 |
| Support Level | $6.81 | $37.78 |
| Resistance Level | N/A | $41.21 |
| Average True Range (ATR) | 0.83 | 1.25 |
| MACD | 0.15 | 0.31 |
| Stochastic Oscillator | 82.66 | 96.35 |
Price Performance
Historical ComparisonAbout REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. The company is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.